Clinical Trials Logo

Filter by:
NCT ID: NCT00241228 Completed - Shock, Septic Clinical Trials

Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)

IVOIRE
Start date: October 2005
Phase: N/A
Study type: Interventional

Sepsis and septic shock are still important causes of mortality in intensive care medicine. Renal replacement therapy by standard volume haemofiltration is currently used, but a higher-volume haemofiltration may improve the prognosis. The study is a prospective randomized multicenter trial comparing two treatments in patients suffering from septic shock complicated with acute renal failure admitted to ICU. One group will be treated by early high volume haemofiltration (70 ml/kg/h) and the second group by standard volume haemofiltration (35 ml/kg/h). The main outcome will be one-month mortality.

NCT ID: NCT00240643 Completed - Atrial Fibrillation Clinical Trials

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.

NCT ID: NCT00240474 Completed - Hypertension Clinical Trials

A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)

Start date: December 2002
Phase: Phase 4
Study type: Interventional

The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.

NCT ID: NCT00240331 Completed - Renal Failure Clinical Trials

AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.

NCT ID: NCT00240318 Completed - Clinical trials for Coronary Arteriosclerosis

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

Start date: November 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries

NCT ID: NCT00239421 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 2003
Phase: Phase 4
Study type: Interventional

To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol plus fluticasone in COPD patients.

NCT ID: NCT00239330 Completed - Hypercholesteremia Clinical Trials

Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy

Start date: June 2003
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.

NCT ID: NCT00238537 Completed - Stroke Clinical Trials

Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)

Start date: August 2001
Phase: Phase 2
Study type: Interventional

To determine whether the extent of the ischemic penumbra apparent on perfusion-diffusion MRI can be used to identify patients who would respond positively and safely to tissue plasminogen activator (tPA) beyond 3 hours post-stroke.

NCT ID: NCT00237939 Completed - Schizophrenia Clinical Trials

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Start date: September 2002
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.

NCT ID: NCT00235755 Completed - Clinical trials for Partial-Onset Seizures

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

RESTORE2
Start date: December 2005
Phase: Phase 3
Study type: Interventional

This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).